Skip to content

News Releases

Filter Releases
 
News Releases
Date Title and Summary View
Mar 1, 2016
SOUTH SAN FRANCISCO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016, at 9:20 a.m. Eastern Time. A live webcast of...
Jan 11, 2016
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/11/16 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced an update on its evofosfamide program including that Threshold and Merck KGaA, Darmstadt, Germany have agreed upon key terms for the licensing back of all rights to evofosfamide to Threshold. The companies have a global license...
Dec 18, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/18/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it has initiated a significant reduction in its workforce in order to focus the company's financial resources in the near term on two ongoing Phase 2 proof-of-concept clinical trials of tarloxotinib bromide* ("tarloxotinib"...
Dec 7, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/07/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the outcomes of two Phase 3 cancer studies (MAESTRO and TH-CR-406/SARC021) of evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, which is being evaluated for first-line treatment of advance...
Nov 18, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/18/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck KGaA, Darmstadt, Germany pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the...
Nov 11, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/11/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Stifel 2015 Healthcare Conference on November 17, 2015, at 1:30 p.m. Eastern Time. A live webcast of the presenta...
Nov 6, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/06/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced new preclinical data demonstrating that tarloxotinib bromide*, or tarloxotinib, may overcome resistance to first- and second- and third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The ...
Nov 3, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/03/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that preclinical data on the combination of evofosfamide with immune checkpoint inhibitors will be presented in a scientific poster at the Society for Immunotherapy of Cancer (SITC) annual meeting in Maryland, November 4-8, 20...
Nov 2, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/02/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the third quarter 2015. Revenue for the third quarter ended September 30, 2015 was $3.7 million. The operating loss for the third quarter ended September 30, 2015 was $6.8 million. The net loss for the thi...
Oct 27, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/27/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it will present preclinical data on tarloxotinib bromide*, or "tarloxotinib", in two scientific posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held Novem...
Oct 13, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/13/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first two U.S. patents protecting tarloxotinib bromide*, or "tarloxotinib," the Company's proprietary hypoxia-activated, irreversible epidermal growth factor rece...
Sep 8, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/08/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the appointment of Mark Hopkins, J.D., Ph.D., as Vice President of Intellectual Property and Assistant General Counsel. In this newly created position, Dr. Hopkins will oversee worldwide intellectual property strategy and acti...
Sep 3, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/03/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Rodman & Renshaw Annual Global Investment Conference on September 10, 2015, at 11:15 a.m. Eastern Time. A live w...
Aug 27, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/27/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the company has initiated a Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib" (TH-4000), for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) or s...
Aug 11, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/11/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the company, in collaboration with the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), has initiated the first Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib" (TH-4000), for the tre...